Related Experiment Videos
Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS
1Albert Einstein College of Medicine, New Hyde Park, New York, USA.
Abstract:
Rifabutin, a macrophage-penetrating lipophilic rifamycin, has a long half-life and activity in vitro against Mycobacterium avium complex (MAC). Preliminary studies of patients with AIDS and those with AIDS-related complex defined dose-limiting toxic effects (arthralgia/arthritis and uveitis) and suggested that rifabutin alone might reduce the incidence of MAC infections. Two double-blind, randomized, placebo-controlled trials involving 1,100 subjects confirmed the safety and efficacy of low doses of rifabutin; this therapy halved the rate of MAC bacteremia and significantly reduced symptoms associated with disseminated MAC infections. Subsequent experience with rifabutin as prophylaxis for and treatment of MAC infections has generally supported its safety profile. Emergence of drug-resistant MAC causing infection in patients receiving rifabutin therapy has not been reported. Interactions with azoles and macrolides increase blood levels of rifabutin and have led to the development of uveitis in certain patients. Studies of the cost-effectiveness of rifabutin prophylaxis for MAC infection suggest that it is comparable with other preventive interventions employed in clinical practice.
Insights
Rifabutin effectively prevents Mycobacterium avium complex (MAC) infections in AIDS patients. Low-dose rifabutin therapy significantly reduces MAC bacteremia and associated symptoms, demonstrating safety and efficacy.
Area of Science:
- Pharmacology
- Infectious Diseases
- Immunology
Background:
- Mycobacterium avium complex (MAC) poses a significant infection risk for individuals with Acquired Immunodeficiency Syndrome (AIDS).
- Rifabutin, a lipophilic rifamycin, exhibits in vitro activity against MAC and penetrates macrophages.
- Preliminary studies indicated potential efficacy of rifabutin in reducing MAC incidence, with dose-limiting toxicities including arthralgia/arthritis and uveitis.
Purpose of the Study:
- To evaluate the safety and efficacy of low-dose rifabutin for the prevention and treatment of MAC infections.
- To confirm the clinical benefit of rifabutin in a large patient cohort.
Main Methods:
- Two double-blind, randomized, placebo-controlled trials were conducted.
- A total of 1,100 subjects participated in the trials.
- The study assessed MAC bacteremia rates and disseminated MAC infection symptoms.
Main Results:
- Low-dose rifabutin therapy halved the rate of MAC bacteremia.
- Significant reduction in symptoms associated with disseminated MAC infections was observed.
- Rifabutin demonstrated a generally favorable safety profile in subsequent clinical experience, with no reported emergence of drug-resistant MAC.
Conclusions:
- Low-dose rifabutin is a safe and effective option for preventing and treating MAC infections in at-risk populations.
- Rifabutin therapy offers significant clinical benefits in reducing MAC-related morbidity.
- Cost-effectiveness analyses suggest rifabutin prophylaxis is comparable to other preventive strategies.